US Patent

US10952998 — Amlodipine formulations

Formulation · Assigned to Silvergate Pharmaceuticals Inc · Expires 2037-10-06 · 11y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects stable amlodipine oral liquid formulations for treating hypertension and Coronary Artery Disease.

USPTO Abstract

Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Drugs covered by this patent

amlodipine-benzoate (AMLODIPINE BENZOATE)

Patent Metadata

Patent number: US10952998
Jurisdiction: US
Classification: Formulation
Expires: 2037-10-06
Drug substance claim: No
Drug product claim: Yes
Assignee: Silvergate Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.